Orexo announces positive outcome from an in-vivo study of OX390
Uppsala, Sweden – Orexo AB, today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX drug delivery technology. The study results mark an important milestone in the development of OX390, an emergency treatment to reverse overdoses involving xylazine and medetomidine, alpha-2 agonists often referred to as “Tranq” and “Rhino Tranq”, respectively.
The study demonstrated rapid and substantial intranasal absorption of atipamezole, successfully establishing proof-of-concept across multiple formulations. The results support that a single nasal dose of OX390 achieves exposure within the targeted therapeutic range. The next milestone in the project is an upcoming type C meeting with the FDA to agree on the non-clinical development plan that will enable human clinical trials.
Ed Kim, Chief Medical Officer of Orexo, said: “OX390 is a potentially life-saving treatment and likely to be the world’s first medical countermeasure (MCM) to the rising threat from xylazine and medetomidine. With the robust results from the in-vivo study we will proceed with the development of OX390 with strong confidence in OX390’s viability for nasal delivery of atipamezole. Overdoses involving an alpha-2 agonist is on the rise in the US and is a rapidly evolving threat to public health in the United States. Orexo is leading the development of a highly needed treatment, and we look forward to the next milestone, the type C meeting with FDA.”
Nikolaj Sorensen, CEO & President of Orexo, said: “I am very pleased with the in-vivo results, it clearly supports the continued development of OX390 and is another proof-of-concept not only for OX390, but also for Orexo’s proprietary AmorphOX technology. Once again nasal delivery using the AmorphOX technology is confirmed to provide rapid absorption and high bioavailability.”
This project has been supported in whole or in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50125C00010.
For more information, please visit www.orexo.com.
Total Page Views: 77
